Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR M… Ended

2023-509776-41-00 Non-small cell lung cancer (NSCLC) 3 2021-06-30
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended

2024-513870-23-00 Locally Advanced or Metastatic Unresectable Urothelial 5 2021-06-28
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M… Ended

2023-506315-17-00 Advanced melanoma with brain metastases, PD-1 refracto 9 2021-06-25
ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS Ended

2024-515353-24-00 Patients with high risk myelodysplastic syndrome or acu 4 2021-06-22
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c… Ended

2024-514803-33-00 Non-small cell lung cancer (NSCLC) 4 2021-06-16
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) Ended

2022-500821-34-00 Advanced Solid Tumors 1 2021-06-15
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel… Ended

2023-509155-14-00 Peripheral T-cell Lymphoma 4 2021-06-10
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended

2023-503280-42-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2021-06-01
A Study of BMS-986012 in Combination with Carboplatin, Etoposide, andNivolumab as First-line Therapy in Extensive-stage Small Cell Lung Canc… Ended

2024-510700-36-00 Extensive-stage Small Cell Lung Cancer 4 2021-06-01
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cy… Ended

2023-507497-40-00 Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicu 1 2021-05-31
Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL… Ended

2024-510979-38-00 Relapsed or refractory Classical Hodgkins Lymphoma and 4 2021-05-27
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or R… Ended

2024-512640-36-00 Multiple Myeloma 3 2021-05-26
A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancer Ended

2023-503391-24-00 Urothelial cancer 4 2021-05-26
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 treatment-naïve or relapsed/refractory chronic lymphocy 4 2021-05-20
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib … Ended

2022-503107-21-00 NRAS-mutant advanced cutaneous melanoma 3 2021-05-14
Tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and tusamitamab ravtansine (SAR408701) in combination with pembrolizuma… Ended

2023-509115-84-00 Cancer 4 2021-05-12
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab… Ended

2023-507317-10-00 Locally advanced, unresectable, or metastatic non small 5 2021-05-10
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
Efficacy of antibodies targeting PD1 protein in patients with advanced or metastatic tumors that express high levels of PD1 biomarker. Ended

2023-508549-41-00 Metastatic disease 4 2021-04-30
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae … Ended

2024-515510-41-00 Head and neck cancer 4 2021-04-28
The bilateral sentinel node detection rate of fluorescent indocyanine green compared to 99mTc and blue dye inthe sentinel node procedure in … Ended

2024-511966-36-00 cervical cancer stage I-IIA 11 2021-04-26
An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad… Ended

2023-506285-31-00 Locally Advanced or Metastatic Solid Tumors 1 2021-04-21
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Stage IV non small-cell lung cancer 5 2021-04-21
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer Ended

2024-513316-10-00 Adult subjects with de novo or treatment-emergent neuro 3 2021-04-20